Judah Frommer

Stock Analyst at Morgan Stanley

(2.66)
# 539
Out of 5,329 analysts
191
Total ratings
58.87%
Success rate
31.52%
Average return
43 Stocks
Name Action PT Current % Upside Ratings Updated
BPMC Blueprint Medicines
Assumes: Equal-Weight
120 100
99.27 0.74% 1 Mar 20, 2025
CLDX Celldex Therapeutics
Initiates Coverage On: Overweight
46
20.75 121.69% 1 Mar 20, 2025
ABVX Abivax
Assumes: Equal-Weight
12
6.92 73.41% 1 Mar 20, 2025
RGNX Regenxbio
Maintains: Overweight
22 24
9.87 143.16% 2 Mar 14, 2025
GLPG Galapagos
Downgrades: Underweight
31 22
26.79 -17.88% 3 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
8 6
3.44 74.42% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
31
20.09 54.31% 1 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
81 106
65.69 61.36% 2 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
35
14.79 136.65% 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
2.58 403.88% 1 Apr 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Equal-Weight
3
0.86 248.84% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40
5.38 643.49% 8 Aug 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4
n/a n/a 3 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.07 1114.95% 5 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
32.74 -8.37% 8 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
23
9.88 132.79% 5 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
50
49.5 1.01% 9 Jul 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
141
62.8 124.52% 13 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.22 965.57% 5 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
9
1.47 512.24% 5 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
175 138
n/a n/a 6 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 22
19.99 10.06% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
8 7
4.88 43.44% 3 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 1
n/a n/a 4 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
11 8
4.38 82.65% 5 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
12.22 276.43% 5 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
7 7
0.98 614.29% 6 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
51 55
14.98 267.16% 3 Feb 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
72.77 -36.79% 1 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 4
n/a n/a 1 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
14 10
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 49
81.33 -39.75% 4 Nov 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
328 370
999.91 -63% 2 Oct 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 31
66.33 -53.26% 6 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 76
70.14 8.35% 8 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
182
90.62 100.84% 6 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
107
81.34 31.55% 13 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
90 95
106.51 -10.81% 10 Jul 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
18
22.02 -18.26% 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
93 116
75.49 53.66% 12 Jun 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 38
117.33 -67.61% 4 May 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 22
171.54 -87.18% 1 May 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
33 35
72.21 -51.53% 9 Apr 29, 2020